Phase 3
Completed N=254
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov NCT02916706 ↗Enrolled (actual)
254
Serious AEs
3.9%
Results posted
Jan 2022
Primary outcomePrimary: Change in HbA1c From Baseline to Week 24 — -0.95; -0.14 percentage of HbA1c
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in HbA1c From Baseline to Week 24 |
-0.95; -0.14 | — |
| SECONDARY The Changes in Fasting Plasma Glucose (FPG) at Week 24 |
-21.9; -1.4 | — |
Eligibility Criteria
Inclusion Criteria
- A signed and dated informed consent form has been obtained from the subject, in accordance with International Conference on Harmonisation guidelines on Good Clinical Practice (ICH GCP), before any screening or study related procedures take place.
- The subject is aged ≥18 years at signature of the informed consent form.
- Hospitalization status: outpatient.
- The subject has had a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit (Day -28).
- The subject is undergoing diet and exercise therapy, and diet and exercise regimen has not been changed for at least 8 consecutive weeks at the screening visit (Day -28). Subjects who cannot do exercise due to complication are not limited to this criteria.
- The subject's glycosylated fraction of haemoglobin(HbA1c) is ≥ 7.0% and < 10.0% at the screening visit (Day -28) and on Day -14.
Exclusion Criteria
- The subject has a history of type 1 diabetes mellitus or a secondary form of diabetes.
- The subject has received insulin within 1 year prior to the screening visit (Day -28), with the exception of insulin therapy during hospitalization or insulin therapy for medical conditions not requiring hospitalization (< 2 weeks' duration).
- The subject has received an anti-diabetic drug within 8 weeks prior to the screening visit (Day -28).
Data sourced from ClinicalTrials.gov (NCT02916706). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.